MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
24.40
-0.35
-1.39%
Opening 14:53 10/06 EDT
OPEN
24.74
PREV CLOSE
24.74
HIGH
24.84
LOW
23.96
VOLUME
451.06K
TURNOVER
--
52 WEEK HIGH
31.74
52 WEEK LOW
13.61
MARKET CAP
3.11B
P/E (TTM)
-6.2481
1D
5D
1M
3M
1Y
5Y
1D
ARC 20 Data Event Might Change The Case For Investing In Arcus Biosciences Stock (RCUS)
Simply Wall St · 1d ago
Arcus Maintained at Hold as Balanced Risk-Reward Persists; $29 Price Target Reaffirmed
TipRanks · 1d ago
Weekly Report: what happened at RCUS last week (0928-1002)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Shattuck Labs (STTK) and Arcus Biosciences (RCUS)
TipRanks · 1d ago
Arcus Biosciences Ran While The Harder Question Stayed Open
Simply Wall St · 2d ago
Arcus Biosciences (RCUS) Dropped, What Is Behind The Latest Attention?
Simply Wall St · 4d ago
Mizuho biotech analysts hold an analyst/industry conference call
TipRanks · 4d ago
Analysts Are Bullish on These Healthcare Stocks: Spruce Biosciences (SPRB), Arcus Biosciences (RCUS)
TipRanks · 6d ago
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.